Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) predominantly affects individuals aged > 60 years who have several comorbidities. Nintedanib is an approved treatment for IPF, which reduces the rate of decline in forced vital capacity (FVC). We assessed the efficacy and safety of nintedanib in pat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Respir Res
Main Authors: Glaspole, Ian, Bonella, Francesco, Bargagli, Elena, Glassberg, Marilyn K., Caro, Fabian, Stansen, Wibke, Quaresma, Manuel, Orsatti, Leticia, Bendstrup, Elisabeth
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2021
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073950/
https://ncbi.nlm.nih.gov/pubmed/33902584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01695-y
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker